Skip to main content
. Author manuscript; available in PMC: 2017 Apr 1.
Published in final edited form as: Crit Rev Oncol Hematol. 2016 Jan 21;100:46–56. doi: 10.1016/j.critrevonc.2016.01.015

Figure 2.

Figure 2

Graphical depiction of the common short comings of nucleoside analogs. A) Inconvenient administration, B) Minimal blood brain barrier penetration at standard doses, C) Rapid elimination and short half-life D) Do not penetrate the tumor cell membrane.